Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12187MR)

This product GTTS-WQ12187MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12187MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4446MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ9610MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ7362MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ11646MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ4814MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ10037MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ8107MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ838MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW